{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-005802","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2025-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.630971+00:00","generated_at":"2026-05-25T16:39:21.716341+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"TG Therapeutics posts Q4 net income $23.3M; FY 2024 BRIUMVI revenue $310M, guides 2025 global rev ~$540M","bullets":["Q4 2024 BRIUMVI U.S. net revenue $103.6M; full year $310M, representing ~250% YoY growth.","Net income of $23.3M in Q4 2024 vs net loss of $14.4M in Q4 2023; full year net income $23.4M.","2025 guidance: total global revenue ~$540M, including BRIUMVI U.S. net revenue ~$525M; operating expenses ~$300M.","Cash, cash equivalents and investments $311M as of Dec 31, 2024; company expects sufficient funding from revenues.","Pipeline: Phase 1 trials for subcutaneous ublituximab in MS and MG; licensed azer-cel CAR T for autoimmune indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-005802","json":"https://secwatch.observer/filing/0001437749-25-005802.json","markdown":"https://secwatch.observer/filing/0001437749-25-005802.md","text":"https://secwatch.observer/filing/0001437749-25-005802.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/0001437749-25-005802-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000143774925005802/tgtx20250225_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T16:39:21.716341+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}